ACOR : Summary for Acorda Therapeutics, Inc. - Yahoo Finance

U.S. Markets open in 7 hrs 58 mins

Acorda Therapeutics, Inc. (ACOR)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
25.300.00 (0.00%)
At close: 4:00PM EST
People also watch
AMAGALNYACADBMRNACHN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close25.30
Open25.15
Bid24.50 x 500
Ask30.00 x 100
Day's Range24.70 - 25.55
52 Week Range16.40 - 37.36
Volume461,713
Avg. Volume741,926
Market Cap1.17B
Beta1.46
PE Ratio (TTM)-50.20
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
    Insider Monkey3 days ago

    Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)

    In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such as Roxane, Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), and Mylan NV (NASDAQ:MYL) as well as ensure it keeps its patents. This is according to Michael Yee, an RBC analyst. Ten companies have been sued […]

  • Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
    Capital Cube4 days ago

    Acorda Therapeutics, Inc. :ACOR-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017

    Categories: Yahoo Finance Get free summary analysis Acorda Therapeutics, Inc. reports financial results for the year ended December 31, 2016. Highlights Gross margins narrowed from 81.14% to 79.19% compared to the same period last year, operating (EBITDA) margins now -1.89% from 12.16%. Narrowing of operating margins contributed to decline in earnings. The table below shows the preliminary results ... Read more (Read more...)

  • Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC
    Investor's Business Daily4 days ago

    Acorda Must Stave Off Mylan, Teva Generics To Protect Ampyra: RBC

    Acorda must keep its patents and stave off generic competition to extend protection of MS drug Ampyra out to 2026, analysts say.